Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Safety Study of Intravenous Infusion of Bone Marrow Mesenchymal Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia

Trial Profile

A Safety Study of Intravenous Infusion of Bone Marrow Mesenchymal Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for Bronchopulmonary Dysplasia

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UNEX 42 (Primary)
  • Indications Bronchopulmonary dysplasia
  • Focus Adverse reactions
  • Sponsors United Therapeutics Corporation

Most Recent Events

  • 27 May 2021 Status changed from active, no longer recruiting to discontinued due to a business decision; no safety concerns were noted.
  • 24 Feb 2021 Status changed from recruiting to active, no longer recruiting.
  • 28 Oct 2020 According to an United Therapeutics Corporation media release, this study was halted in Feb 2020 due to Covid 19 pandemic. However, the study has been resumed now.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top